Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.

<h4>Introduction</h4>Although second-line immunotherapy obtained better outcomes than chemotherapy for patients with advanced non-small-cell lung cancers (NSCLCs), it is expensive and only a minority of patients seem to benefit, based on early tumor progression post-immunotherapy. Notabl...

Full description

Bibliographic Details
Main Authors: Matthieu Dusselier, Elise Deluche, Nellie Delacourt, Julia Ballouhey, Thomas Egenod, Boris Melloni, Charlotte Vergnenègre, Rémi Veillon, Alain Vergnenègre
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0219060

Internet

https://doi.org/10.1371/journal.pone.0219060

Similar Items